Print ArticleInvitrogen Corporation (Nasdaq:IVGN), a leading life sciences company with a broad portfolio of technologies to improve and accelerate biomedical research, drug discovery and commercial bioproduction, unveiled its latest concept in bioinformatics and systems biology with the launch of i-Path at the BIO 2005 international conference.
A new resource for scientists worldwide, i-Path consists of 225 high-level, annotated, validated original maps of human cell signaling and metabolic pathways compiled by GeneGo Inc, a leading provider of databases and software for systems biology. Invitrogen scientists have further identified the specific antibodies, siRNA, full-length DNA clones and other biological molecules involved in cell function and disease on these maps. The system enables researchers to visualize molecular interactions in a highly graphical, user-friendly, interactive format and will be available to scientists free of charge on Invitrogen's Web site."i-Path continues our tradition of providing enabling, Web-based technologies to support researchers throughout their experiments," said Michael Stapleton, Vice President & General Manager eCommerce and Bioinformatics for Invitrogen. "Building on a rich history that includes the acquisition of InforMax, Invitrogen has moved powerful design and analytic capabilities into the mainstream of science by coupling these systems with familiar research tools and making them freely available through our Web site."
"i-Path continues our tradition of providing enabling, Web-based technologies to support researchers throughout their experiments," said Michael Stapleton, Vice President & General Manager eCommerce and Bioinformatics for Invitrogen. "Building on a rich history that includes the acquisition of InforMax, Invitrogen has moved powerful design and analytic capabilities into the mainstream of science by coupling these systems with familiar research tools and making them freely available through our Web site."
i-Path includes maps of pathways that cover more than 2,500 genes --all of them human -- of interest to biotech and pharmaceutical researchers. These include 171 signal transduction pathways representing the majority of known proteins involved in these processes and 54 metabolic pathways representing a significant number of genes involved in drug metabolism. The maps were created and annotated by a team of more than 40 scientists using information from thousands of scientific papers and validated with the accuracy and authenticity of pathways based on the latest scientific consensus. i-Path will also provide a time-saving link to reagents, kits and other Invitrogen research products related to the study of each molecule detailed in the pathway maps.
"With Invitrogen's deep portfolio of research capabilities, we are in a unique position to support systems biology as a driver of life science research and drug discovery," said Gregory T. Lucier, Chairman and CEO of Invitrogen Corporation. "With our latest offerings we are solidifying our Website as the center of scientific conversation about the nature, structure and utility of biologic pathways."
Details about Invitrogen's new bioinformatics initiative will be made available at a news conference at the BIO 2005 conference, 2 p.m., Monday, June 20th in room 203B. Demonstrations will also be available at the Invitrogen booth in the exhibit hall. i-Path will be accessible at www.invitrogen.com/ipath beginning June 20, 2005.
Source : Invitrogen
Mail to a Friend
Link to this article
